Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity.

Quambusch L, Landel I, Depta L, Weisner J, Uhlenbrock N, Müller MP, Glanemann F, Althoff K, Siveke JT, Rauh D.

Angew Chem Int Ed Engl. 2019 Oct 4. doi: 10.1002/anie.201909857. [Epub ahead of print]

PMID:
31584233
2.

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.

Kaissis G, Ziegelmayer S, Lohöfer F, Steiger K, Algül H, Muckenhuber A, Yen HY, Rummeny E, Friess H, Schmid R, Weichert W, Siveke JT, Braren R.

PLoS One. 2019 Oct 2;14(10):e0218642. doi: 10.1371/journal.pone.0218642. eCollection 2019.

3.

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.

Chen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, Bekaii-Saab T, Siveke JT.

Cancers (Basel). 2019 Jul 28;11(8). pii: E1068. doi: 10.3390/cancers11081068.

4.

MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo.

Walter K, Tiwary K, Trajkovic-Arsic M, Hidalgo-Sastre A, Dierichs L, Liffers ST, Gu J, Gout J, Schulte LA, Münch J, Seufferlein T, Sainz B Jr, Siveke JT, Rodriguez-Aznar E, Hermann PC.

Stem Cells Int. 2019 Jun 2;2019:8475389. doi: 10.1155/2019/8475389. eCollection 2019.

5.

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.

Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Müller H, Baumann M, Schultz-Fademrecht C, Günther G, Maghnouj A, Müller MP, Pohl M, Teschendorf C, Wolters H, Viebahn R, Tannapfel A, Uhl W, Hengstler JG, Hahn SA, Siveke JT, Rauh D.

Cancer Res. 2019 May 1;79(9):2367-2378. doi: 10.1158/0008-5472.CAN-18-2861. Epub 2019 Mar 11.

PMID:
30858154
6.

Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.

Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA.

J Geriatr Oncol. 2019 May;10(3):427-435. doi: 10.1016/j.jgo.2019.02.011. Epub 2019 Mar 4.

7.

Still a hopeless case for personalized oncology? Pancreatic cancer revisited.

Weichert W, Sprick MR, Siveke JT.

Oncoscience. 2018 Aug 22;6(1-2):285-286. doi: 10.18632/oncoscience.464. eCollection 2019 Jan. No abstract available.

8.

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.

Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT.

Eur J Cancer. 2019 Feb;108:78-87. doi: 10.1016/j.ejca.2018.12.007. Epub 2019 Jan 14.

9.

Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts.

Westphalen CB, Preinfalk A, Kruger S, Haas M, Renz BW, Riener MO, Weber A, Kirchner T, Werner J, Heinemann V, von Bergwelt-Baildon M, Baba HA, Siveke JT, Ormanns S, Boeck S.

Clin Transl Oncol. 2019 Aug;21(8):1108-1111. doi: 10.1007/s12094-018-02030-6. Epub 2019 Jan 3.

PMID:
30607794
10.

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.

Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT.

Eur J Cancer. 2019 Jan;106:24-33. doi: 10.1016/j.ejca.2018.09.029. Epub 2018 Nov 17.

11.

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.

Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA.

Eur J Cancer. 2018 Dec;105:71-78. doi: 10.1016/j.ejca.2018.09.010. Epub 2018 Nov 8.

12.

A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery.

Schug C, Gupta A, Urnauer S, Steiger K, Cheung PF, Neander C, Savvatakis K, Schmohl KA, Trajkovic-Arsic M, Schwenk N, Schwaiger M, Nelson PJ, Siveke JT, Spitzweg C.

Mol Cancer Res. 2019 Jan;17(1):310-320. doi: 10.1158/1541-7786.MCR-18-0185. Epub 2018 Sep 17.

PMID:
30224540
13.

Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment.

Siveke JT.

J Nucl Med. 2018 Sep;59(9):1412-1414. doi: 10.2967/jnumed.118.214361. Epub 2018 Aug 10. No abstract available.

14.

Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting.

Cheung PF, Neff F, Neander C, Bazarna A, Savvatakis K, Liffers ST, Althoff K, Lee CL, Moding EJ, Kirsch DG, Saur D, Bazhin AV, Trajkovic-Arsic M, Heikenwalder MF, Siveke JT.

Cancer Res. 2018 Sep 1;78(17):4997-5010. doi: 10.1158/0008-5472.CAN-18-0052. Epub 2018 May 29.

15.

Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.

Cheung PF, Lutz M, Siveke JT.

Oncol Res Treat. 2018;41(5):286-290. doi: 10.1159/000488917. Epub 2018 Apr 26. Review.

16.

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

Haas M, Siveke JT, Schenk M, Lerch MM, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, Reinacher-Schick A, Fuchs M, Kanzler S, Kunzmann V, Ettrich TJ, Kruger S, Westphalen CB, Held S, Heinemann V, Boeck S.

Eur J Cancer. 2018 May;94:95-103. doi: 10.1016/j.ejca.2018.02.008. Epub 2018 Mar 20.

PMID:
29549862
17.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6.

PMID:
29508762
18.

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.

Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke JT, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S.

Eur J Cancer. 2018 Mar;92:11-19. doi: 10.1016/j.ejca.2017.12.028. Epub 2018 Feb 3.

PMID:
29413685
19.

Knockdown of myeloid cell hypoxia-inducible factor-1α ameliorates the acute pathology in DSS-induced colitis.

Bäcker V, Cheung FY, Siveke JT, Fandrey J, Winning S.

PLoS One. 2017 Dec 20;12(12):e0190074. doi: 10.1371/journal.pone.0190074. eCollection 2017.

20.

Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.

Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Wörner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, Esposito I, Braren R, Siveke JT.

Sci Rep. 2017 Dec 6;7(1):17038. doi: 10.1038/s41598-017-16826-z.

21.

PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI.

Urban C, Buck A, Siveke JT, Lordick F, Luber B, Walch A, Aichler M.

Biochim Biophys Acta Gen Subj. 2018 Jan;1862(1):51-60. doi: 10.1016/j.bbagen.2017.10.005. Epub 2017 Oct 9.

PMID:
29024724
22.

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.

Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen CB, Siveke JT, Wenzel P, Schlitter AM, Esposito I, Quietzsch D, Clemens MR, Kettner E, Laubender RP, Jung A, Kirchner T, Boeck S, Heinemann V.

Br J Cancer. 2017 May 23;116(11):1462-1469. doi: 10.1038/bjc.2017.115. Epub 2017 Apr 27.

23.

Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.

Schmohl KA, Gupta A, Grünwald GK, Trajkovic-Arsic M, Klutz K, Braren R, Schwaiger M, Nelson PJ, Ogris M, Wagner E, Siveke JT, Spitzweg C.

Oncotarget. 2017 May 16;8(20):33393-33404. doi: 10.18632/oncotarget.16499.

24.

Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.

Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V, Kohlhof H, Hessmann E, Johnsen SA.

Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349. doi: 10.1093/nar/gkx212.

25.

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.

Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA.

Br J Cancer. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67. Epub 2017 Mar 28.

26.

Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.

Lubeseder-Martellato C, Alexandrow K, Hidalgo-Sastre A, Heid I, Boos SL, Briel T, Schmid RM, Siveke JT.

EBioMedicine. 2017 Feb;15:90-99. doi: 10.1016/j.ebiom.2016.12.013. Epub 2016 Dec 24.

27.

Multiparametric 18F-FDG PET/MR follow-up in a patient with autoimmune pancreatitis.

Rauscher I, Eiber M, Algül H, Siveke JT, Weirich G, Schlitter AM, Beer AJ.

Eur J Hybrid Imaging. 2017;1(1):11. doi: 10.1186/s41824-017-0016-9. Epub 2017 Nov 22.

28.

Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?

Hessmann E, Johnsen SA, Siveke JT, Ellenrieder V.

Gut. 2017 Jan;66(1):168-179. doi: 10.1136/gutjnl-2016-312539. Epub 2016 Nov 3. Review.

29.

Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model.

Hidalgo-Sastre A, Brodylo RL, Lubeseder-Martellato C, Sipos B, Steiger K, Lee M, von Figura G, Grünwald B, Zhong S, Trajkovic-Arsic M, Neff F, Schmid RM, Siveke JT.

Am J Pathol. 2016 Nov;186(11):2934-2944. doi: 10.1016/j.ajpath.2016.07.025. Epub 2016 Sep 14.

PMID:
27639167
30.

Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.

Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Eßwein MR, Erkan M, Kleeff J, Jäger C, Friess H, Haller B, Steingötter A, Schmid RM, Schwaiger M, Rummeny EJ, Esposito I, Siveke JT, Braren RF.

Clin Cancer Res. 2017 Mar 15;23(6):1461-1470. doi: 10.1158/1078-0432.CCR-15-2432. Epub 2016 Sep 23.

31.

γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.

Dorneburg C, Goß AV, Fischer M, Roels F, Barth TF, Berthold F, Kappler R, Oswald F, Siveke JT, Molenaar JJ, Debatin KM, Beltinger C.

Oncotarget. 2016 Sep 27;7(39):62799-62813. doi: 10.18632/oncotarget.11715.

32.

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR.

BMC Cancer. 2016 Aug 31;16:699. doi: 10.1186/s12885-016-2736-9.

33.

Membranous CD24 drives the epithelial phenotype of pancreatic cancer.

Lubeseder-Martellato C, Hidalgo-Sastre A, Hartmann C, Alexandrow K, Kamyabi-Moghaddam Z, Sipos B, Wirth M, Neff F, Reichert M, Heid I, Schneider G, Braren R, Schmid RM, Siveke JT.

Oncotarget. 2016 Aug 2;7(31):49156-49168. doi: 10.18632/oncotarget.9402.

34.

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B.

J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4.

PMID:
26952006
35.

Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer.

Grüner BM, Winkelmann I, Feuchtinger A, Sun N, Balluff B, Teichmann N, Herner A, Kalideris E, Steiger K, Braren R, Aichler M, Esposito I, Schmid RM, Walch A, Siveke JT.

Mol Cancer Ther. 2016 May;15(5):1145-52. doi: 10.1158/1535-7163.MCT-15-0165. Epub 2016 Jan 28.

36.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group.

Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.

PMID:
26615328
37.

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.

Diersch S, Wirth M, Schneeweis C, Jörs S, Geisler F, Siveke JT, Rad R, Schmid RM, Saur D, Rustgi AK, Reichert M, Schneider G.

Oncogene. 2016 Jul 21;35(29):3880-6. doi: 10.1038/onc.2015.437. Epub 2015 Nov 23.

38.

Next-generation metabolic imaging in pancreatic cancer.

Braren RF, Siveke JT.

Gut. 2016 Mar;65(3):367-9. doi: 10.1136/gutjnl-2015-310518. Epub 2015 Oct 13. No abstract available.

PMID:
26464413
39.

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT.

Nat Med. 2015 Oct;21(10):1163-71. doi: 10.1038/nm.3952. Epub 2015 Sep 21.

40.

Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.

Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20. doi: 10.1245/s10434-015-4851-2. Epub 2015 Sep 8.

PMID:
26350368
41.

MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.

Hessmann E, Schneider G, Ellenrieder V, Siveke JT.

Oncogene. 2016 Mar 31;35(13):1609-18. doi: 10.1038/onc.2015.216. Epub 2015 Jun 29. Review.

PMID:
26119937
42.

Lineage fate of ductular reactions in liver injury and carcinogenesis.

Jörs S, Jeliazkova P, Ringelhan M, Thalhammer J, Dürl S, Ferrer J, Sander M, Heikenwalder M, Schmid RM, Siveke JT, Geisler F.

J Clin Invest. 2015 Jun;125(6):2445-57. doi: 10.1172/JCI78585. Epub 2015 Apr 27.

43.

Current methods in mouse models of pancreatic cancer.

Mazur PK, Herner A, Neff F, Siveke JT.

Methods Mol Biol. 2015;1267:185-215. doi: 10.1007/978-1-4939-2297-0_9.

PMID:
25636470
44.

A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.

Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J, Michalski CW.

Gut. 2016 Apr;65(4):647-57. doi: 10.1136/gutjnl-2014-307616. Epub 2015 Jan 19.

PMID:
25601637
45.

Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe.

Stangl S, Varga J, Freysoldt B, Trajkovic-Arsic M, Siveke JT, Greten FR, Ntziachristos V, Multhoff G.

Cancer Res. 2014 Dec 1;74(23):6903-12. doi: 10.1158/0008-5472.CAN-14-0413. Epub 2014 Oct 9.

46.

The increasing diversity of KRAS signaling in pancreatic cancer.

Siveke JT.

Gastroenterology. 2014 Oct;147(4):736-9. doi: 10.1053/j.gastro.2014.08.026. Epub 2014 Sep 11. No abstract available.

PMID:
25167989
47.

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.

Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S.

BMC Cancer. 2014 Aug 28;14:624. doi: 10.1186/1471-2407-14-624.

48.

Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.

Kruger S, Haas M, Ormanns S, Bächmann S, Siveke JT, Kirchner T, Heinemann V, Boeck S.

World J Gastroenterol. 2014 Aug 21;20(31):10769-77. doi: 10.3748/wjg.v20.i31.10769. Review.

49.

Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice.

Seubert B, Grünwald B, Kobuch J, Cui H, Schelter F, Schaten S, Siveke JT, Lim NH, Nagase H, Simonavicius N, Heikenwalder M, Reinheckel T, Sleeman JP, Janssen KP, Knolle PA, Krüger A.

Hepatology. 2015 Jan;61(1):238-48. doi: 10.1002/hep.27378. Epub 2014 Nov 24.

50.

Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.

Saugel B, Lee M, Feichtinger S, Hapfelmeier A, Schmid RM, Siveke JT.

J Thromb Thrombolysis. 2015 Jul;40(1):54-60. doi: 10.1007/s11239-014-1124-z.

PMID:
25115839

Supplemental Content

Loading ...
Support Center